1986 Fiscal Year Final Research Report Summary
Lymphokine-Activated Killer Activity of Peripheral Bloood Lymphocytes Isolated from Patients with Oral Cancer.
Project/Area Number |
60570918
|
Research Category |
Grant-in-Aid for General Scientific Research (C)
|
Allocation Type | Single-year Grants |
Research Field |
外科・放射線系歯学
|
Research Institution | Tokyo Medical and Dental University |
Principal Investigator |
KUSAMA Mikio Tokyo Medical and Dental Univ. Fac. of Dentistry, 歯学部, 助手 (60124690)
|
Co-Investigator(Kenkyū-buntansha) |
TAKAHASI Yuzou Tokyo Medical and Dental niv,Fac, of Dentistry, 歯学部, 助手 (50014329)
TAGAMI Tadashi Tokyo Medical and Dental Univ. Fac. of Dentistry, 歯学部, 助手 (50163332)
FUJIBAYASHI Takashi Tokyo Medical and Dental Univ. Fac. of Dentistry, 歯学部, 講師 (80013978)
|
Project Period (FY) |
1985 – 1986
|
Keywords | Oral cancer / Head and Neck Tumor / Immunotherapy / Interleukin-2 |
Research Abstract |
Peripheral blood lymphocytes (PBLs) were isolated from normal donors and patients with oral cancer for study of lymphokine activated killer (LAK) activity. PBLs cultured in vitro for 3-7 days in the presence of recombinant interleukin 2 (RIL2) expressed higher levels of cytotoxicity, as compared to fresh PBLs, against natural killer (NK) susceptible K562 or NK resistant target cells Daudi, NA and Ca-922. When oral cancer cells including nine cases of squamous cell carcinoma and one of mucoepidermoid tumor, freshly isolated from surgical specimens by enzyme digestion, were used as target cells in 4hs <^(51)Cr> release cytotoxicity assay, six of 10 PBLs (=60%,>10% specific lysis) preparations lysed autologous tumor cells after treatment with RIL2 in vitro. Although levels of lysis were relatively low as compared to established Ca. line, the mean of % lysis was 17.9%, the range 0.7-54.0%. These data demonstrates that PBLs from oral cancer patients stimulated in vitro with RIL2 acquire some potential against the autologous tumors.
|